# Advicenne Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/advicenne-pharma

- Industry: Pharmaceuticals
- Headquarters: Nimes, France
- Website: www.advicenne.com
- Total disclosed funding: $27M
- Latest round: Series C (May 5, 2017)
- Investors on record: 6

## About

Advicenne Pharma SA is a pharmaceutical company focused on developing and commercializing innovative treatments for rare renal diseases, aiming to improve patient outcomes through specialized therapies.Founded in 2007, Advicenne Pharma SA operates from Nimes, France, and is dedicated to addressing the unmet medical needs of patients with rare renal conditions. The company's founder, Didier Laurens, has a history of leading ventures in the pharmaceutical sector. Advicenne went public in December 2017, raising EUR 27 million through an IPO, and since then has focused on delivering effective solutions for patients. The firm has conducted a total of 6 deals, with its latest funding round being an IPO that raised EUR 27 million, which is also the total amount raised to date.Advicenne specializes in the development and commercialization of innovative pharmaceuticals aimed at addressing the needs of patients suffering from rare renal diseases. Their flagship product, Sibnayal®, combines potassium citrate and potassium bicarbonate to provide a therapeutic solution for patients with Distal Renal Tubular Acidosis (dRTA). Approved in 2021 by both the European Medicine Agency and the UK's MHRA, Sibnayal® is specifically designed to improve metabolic health and manage symptoms associated with rare renal conditions, thereby enhancing the quality of life for users. Advicenne's products are available in multiple geographical markets, including various European nations and the United States, catering to both pediatric and adult patients who have limited therapeutic options. The company targets healthcare providers and institutions, ensuring that their products reach the end users effectively, thus fulfilling a critical gap in the treatment landscape for rare renal diseases.Advicenne generated revenue of EUR 4,825,269.30 in the most recent year, 2023. This revenue is primarily derived from the sales of its pharmaceutical products, including Sibnayal®. The company engages in business-to-business transactions with healthcare providers and partners with pharmaceutical distributors to enhance market penetration. The pricing structures for Sibnayal® and other products reflect the therapeutic value provided, which is integral to Advicenne's revenue model as the company seeks to ensure accessibility while sustaining operations in the regulated pharmaceutical market.Advicenne plans to expand its product offerings and market presence. The company is focusing on the development of additional treatments for rare renal diseases to enhance its portfolio. Furthermore, Advicenne aims to penetrate new geographic markets, particularly targeting regions where there is a high demand for effective renal therapies. Recent funding from the EUR 27 million raised in its IPO will support these initiatives by facilitating research and development activities as well as marketing strategies.

## Funding rounds

- Series C, May 5, 2017, $17M — IXO Private Equity, Soridec, Bpifrance Investissement, Cemag Invest, MI Care, Irdi Capital Investissement
- Series B, Jan 30, 2014, $5.2M — IXO Private Equity, Bpifrance Investissement
- Series A, Jul 27, 2011, $5.1M — IXO Private Equity, Bpifrance Investissement

## Investors

- IXO Private Equity (https://capitalatlas.ai/funds/ixo-private-equity) — Series A, Series B, Series C
- Bpifrance Investissement (https://capitalatlas.ai/funds/bpifrance-investissement) — Series A, Series B, Series C
- Soridec — Series C
- Cemag Invest — Series C
- MI Care — Series C
- Irdi Capital Investissement (https://capitalatlas.ai/funds/irdi-capital-investissement) — Series C